ソラフェニブの世界市場レポート 2025年

ソラフェニブの市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.2％で15億3,000万米ドルに成長します。予測期間の成長は、甲状腺がんの罹患率の増加、がんの罹患率の増加、慢性疾患の有病率の増加、精密医療への注目の高まり、肝臓がんと腎臓がんの罹患率の上昇に起因すると考えられます。予測期間における主な動向としては、早期診断・治療の進歩、代替療法の革新、進行肝細胞がん（HCC）、ドラッグデリバリーの技術革新、進行腎細胞がんなどが挙げられます。

がん罹患率の上昇は、今後のソラフェニブ市場の成長を牽引すると予想されます。がんとは、異常細胞の制御不能な増殖と分裂を特徴とする疾患の総称であり、健康な組織に侵入して損傷を与える可能性があります。がんの有病率の増加は、高齢化、ライフスタイルの選択、環境暴露、診断技術の進歩など様々な要因に起因しており、その結果、より多くの症例が特定されています。マルチキナーゼ阻害剤であるソラフェニブは、腫瘍増殖や血管新生に関与する重要なシグナル伝達経路を標的とするため、がん治療において不可欠であり、進行した腎細胞がんや肝細胞がんの患者にとって効果的な治療選択肢となっています。例えば、米国の政府間機関である国立生物工学情報センター（National Center for Biotechnology Information）は、2023年1月に約195万8,310人の新規がん患者と60万9,820人のがん関連死亡者を報告しました。このように、がんの有病率の増加がソラフェニブ市場の拡大に拍車をかけています。

ソラフェニブ市場の主要企業は、手頃な価格のソラフェニブジェネリック錠剤など、がん治療における特定の要件を満たしながら有効性と患者のアドヒアランスを向上させる革新的な製品の創出に注力しています。手頃な価格のジェネリック医薬品は、先発医薬品と同じ治療効果を持ちながら、はるかに低価格です。これらの医薬品は、先発品と同等の臨床効果を発揮しながら、ヘルスケアコストの削減に貢献しています。例えば、2022年6月、インドの製薬メーカーであるドクター・レディーズ・ラボラトリーズは、米国食品医薬品局（USFDA）の承認を得て、さまざまながんのジェネリック治療薬であるソラフェニブ錠を米国市場に投入しました。このジェネリック医薬品はバイエル社のネクサバールをベースとしたもので、肝臓がん、腎臓がん、甲状腺がんなど複数のがんの治療に使用されます。ソラフェニブの錠剤は200mg用量で、120錠入りのボトルで販売されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ソラフェニブ PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のソラフェニブ市場：成長率分析
• 世界のソラフェニブ市場の実績：規模と成長, 2019-2024
• 世界のソラフェニブ市場の予測：規模と成長, 2024-2029, 2034F
• 世界ソラフェニブ総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のソラフェニブ市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特許医薬品
• ジェネリック医薬品
• 世界のソラフェニブ市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• ドラッグストアと薬局
• オンライン薬局
• 世界のソラフェニブ市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腎臓がん
• 肝臓がん
• 甲状腺がん
• 世界のソラフェニブ市場特許医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ネクサバール
• 世界のソラフェニブ市場ジェネリック医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 一般的なソラフェニブトシル酸塩
• その他のジェネリックバリアント

第7章 地域別・国別分析

• 世界のソラフェニブ市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のソラフェニブ市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ソラフェニブ市場：競合情勢
• ソラフェニブ市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Amgen Inc.
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Dr. Reddy's Laboratories Ltd.
• Exelixis Inc.
• Natco Pharma
• Beacon Pharmaceuticals Ltd.
• Hetero Healthcare Ltd.
• Aprazer Healthcare Private Limited
• Wellona Pharma
• Anant Pharmaceuticals Pvt. Ltd.
• Intelicure Lifescience

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ソラフェニブ市場2029：新たな機会を提供する国
• ソラフェニブ市場2029：新たな機会を提供するセグメント
• ソラフェニブ市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Sorafenib is a medication primarily used in the treatment of certain types of cancer. It is classified as a targeted therapy drug, functioning by inhibiting specific enzymes and proteins that are involved in cancer cell growth and the formation of blood vessels in tumors.

The main product types of sorafenib include patented drugs and generic drugs. Patented drugs are medications protected by intellectual property rights, usually through a patent granted to the company or individual who discovered or developed the drug. Sorafenib is distributed through various channels, including hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. It is used in the treatment of several conditions, including kidney cancer, liver cancer, and thyroid cancer.

The sorafenib market research report is one of a series of new reports from The Business Research Company that provides sorafenib market statistics, including sorafenib industry global market size, regional shares, competitors with a sorafenib market share, detailed sorafenib market segments, market trends, and opportunities, and any further data you may need to thrive in the sorafenib industry. This sorafenib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sorafenib market size has grown steadily in recent years. It will grow from $1.24 billion in 2024 to $1.3 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to favorable government policies and reimbursement programs, increasing approvals for new drugs, increasing apoptosis in cancer cells, rising incidence of target cancers, and growing research studies on sorafenib.

The sorafenib market size is expected to see steady growth in the next few years. It will grow to $1.53 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to the increasing incidence of thyroid cancer, increasing incidence of cancer, increase in prevalence of chronic diseases, increasing focus on precision medicine, and rising incidence of liver and renal cancers. Major trends in the forecast period include advancements in early diagnosis and treatment, innovations in alternative therapies, advanced hepatocellular carcinoma (HCC), technological innovations in drug delivery, and advanced renal cell carcinoma.

The rising incidence of cancer is anticipated to drive the growth of the sorafenib market in the future. Cancer refers to a collection of disorders characterized by the uncontrolled growth and division of abnormal cells, which can invade and damage healthy tissues. The increasing prevalence of cancer can be attributed to various factors, including an aging population, lifestyle choices, environmental exposures, and advancements in diagnostic technologies that result in more cases being identified. Sorafenib, a multi-kinase inhibitor, is essential in cancer treatment as it targets critical signaling pathways involved in tumor growth and angiogenesis, making it an effective therapeutic option for patients with advanced renal cell carcinoma and hepatocellular carcinoma. For example, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, reported approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths in 2023. Thus, the increasing prevalence of cancer is fueling the expansion of the sorafenib market.

Key players in the sorafenib market are concentrating on creating innovative products, such as affordable generic sorafenib tablets, to improve efficacy and patient adherence while meeting specific requirements in cancer treatment. Affordable generic medicines provide the same therapeutic benefits as their brand-name counterparts but at much lower prices. These medications help to lower healthcare costs while delivering equivalent clinical efficacy to their branded versions. For instance, in June 2022, Dr. Reddy's Laboratories, an Indian pharmaceutical manufacturer, introduced Sorafenib tablets, a generic treatment for various cancers, in the US market after receiving approval from the US Food and Drug Administration (USFDA). This generic product is based on Bayer's Nexavar and is used for treating multiple cancers, including liver, kidney, and thyroid cancers. The Sorafenib tablets are available in 200 mg doses and are sold in bottles containing 120 tablets.

In June 2024, Lotus Pharmaceuticals Co. Ltd., a Taiwan-based company focused on manufacturing and selling generic drugs, acquired Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition allows Lotus Pharmaceuticals to broaden its product range and market presence by integrating Teva's extensive portfolio of pharmaceutical products and expertise. Teva Pharmaceutical Industries Ltd. is an Israel-based company that produces sorafenib tablets.

Major companies operating in the sorafenib market are Pfizer Inc., Bayer AG, AstraZeneca PLC, Novartis AG, Bristol Myers Squibb , Mylan N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Amgen Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Exelixis Inc., Natco Pharma, Beacon Pharmaceuticals Ltd., Hetero Healthcare Ltd., Aprazer Healthcare Private Limited, Wellona Pharma, Anant Pharmaceuticals Pvt. Ltd., Intelicure Lifescience

North America was the largest region in the sorafenib market in 2023. The regions covered in the sorafenib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sorafenib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sorafenib market consists of sales of nexavar, and sorafenib combination tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sorafenib Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sorafenib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sorafenib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sorafenib market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Patented Drugs; Generic Drugs
• 2) By Distribution Channel: Hospital Pharmacies; Drug Store And Retail Pharmacies; Online Pharmacies
• 3) By Application: Kidney Cancer; Liver Cancer; Thyroid Cancer
• Subsegments:
• 1) By Patented Drugs: Nexavar
• 2) By Generic Drugs: Generic Sorafenib Tosylate; Other Generic Variants
• Companies Mentioned: Pfizer Inc.; Bayer AG; AstraZeneca PLC; Novartis AG; Bristol Myers Squibb
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sorafenib Market Characteristics

3. Sorafenib Market Trends And Strategies

4. Sorafenib Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Sorafenib Growth Analysis And Strategic Analysis Framework

• 5.1. Global Sorafenib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Sorafenib Market Growth Rate Analysis
• 5.4. Global Sorafenib Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Sorafenib Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Sorafenib Total Addressable Market (TAM)

6. Sorafenib Market Segmentation

• 6.1. Global Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Patented Drugs
• Generic Drugs
• 6.2. Global Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Store And Retail Pharmacies
• Online Pharmacies
• 6.3. Global Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Kidney Cancer
• Liver Cancer
• Thyroid Cancer
• 6.4. Global Sorafenib Market, Sub-Segmentation Of Patented Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nexavar
• 6.5. Global Sorafenib Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Sorafenib Tosylate
• Other Generic Variants

7. Sorafenib Market Regional And Country Analysis

• 7.1. Global Sorafenib Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Sorafenib Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sorafenib Market

• 8.1. Asia-Pacific Sorafenib Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sorafenib Market

• 9.1. China Sorafenib Market Overview
• 9.2. China Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sorafenib Market

• 10.1. India Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sorafenib Market

• 11.1. Japan Sorafenib Market Overview
• 11.2. Japan Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sorafenib Market

• 12.1. Australia Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sorafenib Market

• 13.1. Indonesia Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sorafenib Market

• 14.1. South Korea Sorafenib Market Overview
• 14.2. South Korea Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sorafenib Market

• 15.1. Western Europe Sorafenib Market Overview
• 15.2. Western Europe Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sorafenib Market

• 16.1. UK Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sorafenib Market

• 17.1. Germany Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sorafenib Market

• 18.1. France Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sorafenib Market

• 19.1. Italy Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sorafenib Market

• 20.1. Spain Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sorafenib Market

• 21.1. Eastern Europe Sorafenib Market Overview
• 21.2. Eastern Europe Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sorafenib Market

• 22.1. Russia Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sorafenib Market

• 23.1. North America Sorafenib Market Overview
• 23.2. North America Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sorafenib Market

• 24.1. USA Sorafenib Market Overview
• 24.2. USA Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sorafenib Market

• 25.1. Canada Sorafenib Market Overview
• 25.2. Canada Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sorafenib Market

• 26.1. South America Sorafenib Market Overview
• 26.2. South America Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sorafenib Market

• 27.1. Brazil Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sorafenib Market

• 28.1. Middle East Sorafenib Market Overview
• 28.2. Middle East Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sorafenib Market

• 29.1. Africa Sorafenib Market Overview
• 29.2. Africa Sorafenib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Sorafenib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sorafenib Market Competitive Landscape And Company Profiles

• 30.1. Sorafenib Market Competitive Landscape
• 30.2. Sorafenib Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

31. Sorafenib Market Other Major And Innovative Companies

• 31.1. Mylan N.V.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Astellas Pharma Inc.
• 31.4. Amgen Inc.
• 31.5. Cipla Limited
• 31.6. Hikma Pharmaceuticals PLC
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. Exelixis Inc.
• 31.9. Natco Pharma
• 31.10. Beacon Pharmaceuticals Ltd.
• 31.11. Hetero Healthcare Ltd.
• 31.12. Aprazer Healthcare Private Limited
• 31.13. Wellona Pharma
• 31.14. Anant Pharmaceuticals Pvt. Ltd.
• 31.15. Intelicure Lifescience

32. Global Sorafenib Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sorafenib Market

34. Recent Developments In The Sorafenib Market

35. Sorafenib Market High Potential Countries, Segments and Strategies

• 35.1 Sorafenib Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Sorafenib Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Sorafenib Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer